PEG & ADCs
- ADC Drugs with New Targets Clinical Pipeline Review
- FDA Approves Tivdak - First Tissue Factor (TF)-Targeted Antibody Conjugate Drug (ADC)
- Global Antibody-drug Conjugates (ADCs): Approvals & Clinical Trails Review
- The History Of ADC Drugs Development
- FDA Approved Antibody-Drug Conjugates Up To 2021
- Antibody Drug Conjugates (ADCs): Novel Linker Design
- History and Development of Antibody Drug Conjugates (ADCs)
- FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) - First CD19-targeted ADC
- Cleavable vs. Non-Cleavable Linkers in Antibody-Drug Conjugates
- A Novel Antibody Drug Conjugate Against Pancreatic Cancer